Boston start­up looks to make a big man­u­fac­tur­ing push with new fund­ing round

As drug man­u­fac­tur­ing star­tups gain more no­to­ri­ety with in­vestors, most no­tably with the re­cent deals sur­round­ing Re­silience, an­oth­er start­up is look­ing to take its next steps in the space on the back of a Se­ries B raise.

Boston-based Elek­trofi, which has been around since 2016, has net­ted a $40 mil­lion Se­ries B round, the com­pa­ny an­nounced Mon­day. Elek­trofi is pri­mar­i­ly fo­cused on man­u­fac­tur­ing sev­er­al kinds of med­i­cines in­clud­ing mon­o­clon­al an­ti­bod­ies, ther­a­peu­tic pro­teins and oth­er large mol­e­cule drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER